Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
Recruiting
Observational Study
Rheumatoid Arthritis (RA)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 90 (estimated)
- Sponsor
- Centre Hospitalier Princesse Grace · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.
The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient aged over 18 years
* Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria
* Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations
* Patient capable of providing in…
Contacts